David Faleck (@DavidFaleckMD) profile picture

Gastroenterologist @sloan_kettering. Focused on IBD, dysplasia, cancer, checkpoint inhibitors, immune-related toxicities

New York, NY
Joined June 2018
Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)Photo by David Faleck (@DavidFaleckMD)
Excited for GI fellow Dr Akram to share our experience @MSKCancerCenter with #IUS for #irEC - the largest to date. 53 pts with paired scope: IUS had high sensitivity (87%) for histologic colitis, captured all Mayo 2-3, BWT tracked with endo severity. Promising tool! #DDW2026
3
232
37F UC pancolitis >10 yrs, on IFX 5mg/kg q4 weeks + AZA 150mg, now dx with skin #melanoma (IIIB). CLN: Mayo 1 panUC, 1cm adenoma/LGD in sigmoid resected. She is planned for neoadjuvant #pembrolizumab + surgery+ adjuvant pembrolizumab x1 year How would you manage her UC therapy?
38%Stop AZA, keep IFX
2%Stop IFX, keep AZA
3%Stop both & Monitor
57%Stop both,Start Vedo/IL23
122 votes • Final results
1
12
1
16
2,551
David Faleck retweeted
Vedolizumab vs standard therapy in checkpoint inhibitor induced colitis an open label RCT @my_ueg #UEGweek by Emilie Kristine Dahl
21
80
3,610
David Faleck retweeted
Novel therapies are revolutionizing the landscape of cancer treatment. Join us in two weeks for a critical forum to explore the evolving landscape of cancer therapeutics, their clinical applications, & evidence-based strategies to mitigate treatment-related toxicities: bit.ly/MSKOTM2025 #MSKOTMCME @MSKCancerCenter @DavidFaleckMD @barton45516 @UrviShahMD @nishjo76 @jamflo2k @DrAlinaMarkova @ipreeshagul @BSantomass @GunjanLShah @stavrou_k
1
6
1
17
5,173
Congrats to our star med student / soon to be IM resident @PatrickMagahis and our team @MSKCancerCenter on this important study of CDI rates and outcomes in >600 pts on cancer immunotherapy
Happy to share our recent @JNCCN study on #Cdiff infection in patients on #immunotherapy p/w diarrhea: 👉Common (18%) 👉⬆️G3-4 diarrhea but antibiotic tx alone sufficient for most 👉24% required steroids for concomitant immune-related enterocolitis (1/2) doi.org/10.6004/jnccn.2024.7…
1
2
11
3,201
55M w/ UC x30y. Prior 5-ASA, 6MP. On IFX 5 mg/kg q8w x5y. Mild UC sx before infusions. 🔦Last scope 1y ago: Mayo 0. Now FCP 141, IFX level 3. New dx: metastatic melanoma → onc is starting nivolumab. What do you recommend for his UC?
17%Stop IFX, monitor on Nivo
37%⬆️IFX 5mg/kg q4wks+Nivo
5%Stop IFX, start Upa+Nivo
41%Stop IFX, start VDZ+Nivo
87 votes • Final results
4
13
15
2,818
At the 🔀of oncology & IBD: Let’s talk #immunotherapy in pts w #IBD 📌Convo @DavidFaleckMD April 28 (Check the🌟B2B🧵on ICI-colitis👇🏽) 🆓#CME 👉🏽bit.ly/MNIBD24-25 🗳️PreConvo CME polls👇🏽 Support by educ grant @abbvie @JanssenUS @TakedaPharma 📍Where are you in your 🩺
47%IBD specialist
26%General GI, CRSurgery
18%Trainee, Fellows
9%Other: Onc APP RN PharmD
68 votes • Final results
1
8
19
3,308
At the 🔀of oncology & IBD: Let’s talk immunotherapy-induced enterocolitis (ICI/IMC) 📌#Back2Basics April14 📌Convo @DavidFaleckMD April28 🆓#CME 👉🏽bit.ly/MNIBD24-25 🗳️PreB2B polls👇🏽 Support by educ grant @abbvie @JanssenUS @TakedaPharma 📍Where are you in your 🩺
45%IBD Specialist
21%General GI/CRSurgery
25%Trainee, Fellow
8%PharmD,APP,RN…
95 votes • Final results
2
15
25
4,827
David Faleck retweeted
Patients with #IBD and a history of cancer who have been treated with various immunosuppressive medications were found to have no greater risk of developing recurrent or new cancers compared to patients with IBD who were not exposed to these medications: ow.ly/2qZV50VmpQi
28
4
57
9,674
David Faleck retweeted
Does the gut #microbiome predispose patients to immunotherapy-related colitis? Our study in @JExpMed explores the #microbiota before, during, and after #colitis induced by #cancer #immunotherapy in a prospective cohort. Read here: hubs.la/Q02_r1nl0 #MedTwitter #GITwitter
.@Shang_Joa, @DavidFaleckMD, @jeremiahfaith1 et al. @IcahnMountSinai report that pretreatment gut #microbiomes of #immunotherapy-related colitis patients drive worse #colitis in susceptible mice compared with non-colitis cancer immunotherapy microbiomes. hubs.la/Q02_r1nl0
1
8
18
4,371
In @JExpMed, @Shang_Joa, @DavidFaleckMD, @jeremiahfaith1 et al. report that pretreatment gut #microbiomes of #immunotherapy-related colitis patients drive worse #colitis in susceptible mice compared with non-colitis cancer immunotherapy microbiomes. hubs.la/Q02_rp9_0
4
5
882
Here’s a closer look at recent #JITC article “Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors” by @PatrickMagahis & @DavidFaleckMD from @WeillCornell & @MSKCancerCenter. 1/11
1
2
4
759
Happy to share our experience using open capsule budesonide for successful treatment of immune-related enteritis. Grateful for my fantastic team @MSKCancerCenter who help treat these pts and made this study possible and ⭐️ med student @PatrickMagahis for putting this together.
New #JITC article: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors bit.ly/4daLo9Z @PatrickMagahis @DavidFaleckMD
2
10
3,984
Thank you Dr Neil Shah @MSKCancerCenter for the keynote invite to the #MSKOTMCME —impressive multidisciplinary science-driven approach to immune-related toxicities! @SashaGusevPosts @maxinesun @eddy_saad @DanaFarber @DanaFarber_GU
1
8
30
3,992
David Faleck retweeted
Join us June 20 for the Oncologic Toxicity Management Symposium #MSKOTMCME. Expert faculty will present a cutting-edge, multidisciplinary approach to managing adverse events from modern oncology treatments. Learn more about this exciting program: bit.ly/OTMsymposium
5
5
911
Outstanding work @TanishaKalra14 expanding our knowledge of #immunotherapycolitis, in particular the underappreciated long duration of symptoms (>12 weeks) in many of our patients @MSKCancerCenter Keep up the good work!
Reflecting on #DDW2024 which was such a great mix of learning, meeting old friends and making new ones! Thankful for the opportunity to present our study. Always grateful to @DavidFaleckMD for making me a part of it and guiding me through the process! #GITwitter #MedTwitter
2
381
David Faleck retweeted
Join us for a vital update on advancements in diagnosing, treating, & monitoring #GI premalignant & malignant conditions. Don't miss out on expert-led discussions covering Barrett's esophagus, hepatocellular carcainoma, & more #MSKgastroCME Register at bit.ly/MSKGI2024
1
1
1
862
New #JITC article: Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series bit.ly/3Umnd23 @harvey_catriona @SerineLo @McQuadeMDLAc @MattCarlino @ProfGLongMIA @ProfCUBlankNKI
8
2
16
5,500